Advancing paediatric allergy care: key findings from the largest trial of house dust mite sublingual immunotherapy-tablets in children
Saved in:
| Main Authors: | Ann-Marie Malby Schoos, Bo Chawes |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | The Lancet Regional Health. Europe |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776224003363 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of house dust mite sublingual immunotherapy in patients with adult atopic dermatitis with rhinitis
by: Mayuko Mizuno, et al.
Published: (2024-12-01) -
House dust mite allergy – Management
by: P. C. Kathuria, et al.
Published: (2024-12-01) -
Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients
by: Kang Zhu, et al.
Published: (2021-01-01) -
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trialResearch in context
by: Antje Schuster, et al.
Published: (2025-01-01) -
Chitooligosaccharides suppress airway inflammation, fibrosis, and mucus hypersecretion in a house dust mite-induced allergy model
by: Yun-Ho Kim, et al.
Published: (2025-01-01)